GLP-1 Receptor Agonists in Psoriatic Arthritis Outcomes

NEW real-world evidence shows that GLP-1 receptor agonists significantly reduce joint pain and inflammation in psoriatic arthritis. Patients living with psoriatic arthritis frequently experience a heavy metabolic disease burden, with concomitant obesity operating as a primary driver of heightened systemic inflammation, severe disease activity, and reduced response to biological therapies. To evaluate the therapeutic potential of metabolic intervention, a retrospective analysis of two clinical cohorts examined forty-eight adults with psoriatic arthritis who initiated treatment with glucagon-like peptide 1 receptor agonists. Researchers tracked longitudinal changes in joint disease activity, overall body weight, and key cardiometabolic markers across the cohort.